Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s13058-020-01294-7
Published Online: 2020-05-20
Published Print: 2020-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
Goldstein, Lori J.
Perez, Raymond P.
Yardley, Denise
Han, Linda K.
Reuben, James M.
Gao, Hui
McCanna, Susan
Butler, Beth
Ruffini, Pier Adelchi
Liu, Yi
Rosato, Roberto R.
Chang, Jenny C.
Text and Data Mining valid from 2020-05-20
Version of Record valid from 2020-05-20
Article History
First Online: 20 May 2020